The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1459
January 5, 2015
View Complete Issue         Table of Contents 2019 
Triumeq: A 3-Drug Combination for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Triumeq: A 3-Drug Combination for HIV
January 5, 2015 (Issue: 1459)
The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine, for once-daily treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Triumeq: A 3-Drug Combination for HIV
Article code: 1459e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.